Biogen Idec, Inc. (North Carolina)
5000 Davis Drive
Research Triangle Park
North Carolina
27709-4627
United States
Tel: 919-993-1100
Fax: 919-941-1112
Website: http://www.biogen.com/
About Biogen Idec, Inc. (North Carolina)
Biogen Idec (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. With its rich scientific heritage and passionate commitment to pioneering new advances, Biogen Idec recognizes that cutting-edge science and medicines can address unmet patient needs to change the course of devastating diseases.
Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $5 billion in annual revenues. Biogen Idec has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (ALS) and hemophilia by 2015.
With about 4,800 employees worldwide, Biogen Idec is a truly global organization. In addition to our headquarters in Weston, Mass., and our research operations in Cambridge, Mass., we have a world-class manufacturing facility in North Carolina and offices in Canada, Australia, Japan and throughout Europe. We also have a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including new markets such as Central/Eastern Europe, Brazil, China and India.
For product labeling, press releases and additional information about the company, please visit www.biogenidec.com
123 articles about Biogen Idec, Inc. (North Carolina)
-
1,075 New Jobs to be Added by 11 Life Science Firms in Massachusetts: Amgen, Alnylam, Biogen Idec, Inc. (North Carolina), GE Healthcare Bio-Sciences, Quest Diagnostics, Alkermes, Baxter Healthcare, Merrimack, Synageva BioPharma, Philips Electronics, SMC
3/23/2015
-
Biogen Idec, Inc. (North Carolina), Eisai Inc. Team Up at Research Triangle Park Facilities
12/12/2012
-
Biogen Idec, Inc. (North Carolina) Opens New RTP Facility
11/30/2012
-
Swedish Orphan Biovitrum's Agreement With Biogen Idec, Inc. (Massachusetts) Regarding Long-Lasting rFVIIIFc and rFIXFc Hemophilia Programs
2/6/2012
-
Biogen Idec, Inc. (North Carolina) and Swedish Orphan Biovitrum AB Announce Decision to Advance Long- Lasting Hemophilia A Therapy into a Registrational Trial
7/9/2010
-
US Judge Finds Biogen, Inc. Breached Pact with Biogen (JOBS)
9/4/2009
-
Elan Corporation PLC's Tysabri May Reverse MS Damage, Shares Up
4/29/2009
-
Biogen Idec, Inc. (Massachusetts) 1st-Quarter Earnings Up But Sales Disappoint
4/17/2009
-
Bristol-Myers Squibb Company (JOBS), Biogen Idec, Inc. (Massachusetts) (JOBS) CEOs: We're Not Rushing to Be Acquired
4/10/2009
-
Biogen Idec, Inc. (Massachusetts) CEO Gets 7 Percent 2008 Compensation Boost
4/2/2009
-
AVEO Pharmaceuticals, Inc. and Biogen Idec, Inc. (Massachusetts) Form Strategic Alliance for Development and Commercialization of ErbB3-Targeted Antibodies
3/24/2009
-
Biogen Idec, Inc. (Massachusetts) Reports Another Tysabri Brain Disease Case
10/30/2008
-
Biogen Idec, Inc. (Massachusetts), Elan Corporation PLC (JOBS) MS Drug Improves Function Over 2 Years
9/22/2008
-
Genentech, Inc. (JOBS) Revises Rituxan Warning After Death
9/12/2008
-
Elan Corporation PLC (JOBS) , Biogen Idec, Inc. (Massachusetts) Launch Tysabri Trial in Oncology
9/5/2008
-
Genentech, Inc. and Biogen Idec, Inc. (Massachusetts) Rituxan May Heal Common Kidney Condition
8/7/2008
-
Hydra Biosciences, Inc. Raises $34M in Venture Capital
3/14/2008
-
Biogen Idec and Neurimmune Announce $380M Alliance to Develop Treatments for Alzheimer's Diseases
11/20/2007
-
BioSpace, BioNJ and Pennsylvania Bio Welcome Over 800 Life Science Career Candidates to Biotech 2007 Career Fair
10/31/2007
-
LigoCyte Pharmaceuticals, Inc. Announces Collaboration With Biogen Idec, Inc. (Massachusetts) to Develop Anti-CD103 Therapies
9/18/2007